Hyperuricemia - Pipeline Review, H2 2020
Hyperuricemia - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperuricemia - Pipeline Review, H2 2020, provides an overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape.
High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history and certain medications. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid medications.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperuricemia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Hyperuricemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 7 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.
Hyperuricemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperuricemia - Pipeline Review, H2 2020, provides an overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape.
High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history and certain medications. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid medications.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperuricemia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Hyperuricemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 7 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.
Hyperuricemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperuricemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hyperuricemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hyperuricemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hyperuricemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hyperuricemia (Metabolic Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hyperuricemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hyperuricemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Hyperuricemia - Overview
Hyperuricemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hyperuricemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hyperuricemia - Companies Involved in Therapeutics Development
Allena Pharmaceuticals Inc
Arthrosi Therapeutics Inc
AstraZeneca Plc
FortuneRock (China) Ltd
Hinova Pharmaceuticals Inc
J-Pharma Co Ltd
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Nippon Chemiphar Co Ltd
NuBioPharma LLC
PegBio Co Ltd
Polaris Pharmaceuticals Inc
Shanghai Yingli Pharmaceutical Co Ltd
Suzhou Sinovent Pharmaceuticals Co Ltd
Teijin Pharma Ltd
Xiuzheng Pharmaceutical Group Co Ltd
Hyperuricemia - Drug Profiles
(allopurinol +verinurad) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABP-671 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALLN-346 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
allopurinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AR-882 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
febuxostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HP-501 SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JPH-367 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NC-2500 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NC-2700 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PB-348 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegadricase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Urate Oxidase Replacement for Acute Hyperuricemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SFR-9350 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-4640 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
taininade - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TEI-A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TMX-049 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
verinurad - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XNW-3009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YL-90148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hyperuricemia - Dormant Projects
Hyperuricemia - Discontinued Products
Hyperuricemia - Product Development Milestones
Featured News & Press Releases
Sep 08, 2020: Allena Pharmaceuticals doses first subject in phase 1 clinical trial of ALLN-346, in development for the treatment of d advanced chronic kidney disease
Oct 30, 2019: AstraZeneca to present pivotal roxadustat phase II data at the American Society of Nephrology Kidney Week 2019
Oct 17, 2019: Allena Pharmaceuticals to present new data on ALLN-346 at upcoming ACR/ARP Annual Meeting
Jul 17, 2019: Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease
Jun 21, 2019: FDA Joint Committee recommends approval of Uloric (Febuxostat)
Jun 13, 2019: Verinurad with febuxostat significantly reduces albuminuria and hyperuricaemia in patients with type ii diabetes in phase iia trial
Jan 11, 2019: Takeda Announces Outcome of FDA Advisory Committee Meeting to Review Uloric (febuxostat) Cardiovascular Outcomes Trial Results
Nov 01, 2018: Selecta Biosciences to provide update on SEL-212 development strategy, including planned head-to-head study versus Krystexxa
Oct 22, 2018: Allena Pharmaceuticals presents preclinical data demonstrating normalized urine uric acid excretion and plasma urate reduction following treatment with ALLN-346
Oct 18, 2018: Allena Pharmaceuticals to present data on Kidney Disease drug candidate ALLN-346 at ACR/ARHP 2018 Annual Meeting
Jun 19, 2018: Allena Pharmaceuticals Completes Animal Proof-of-Concept Study for ALLN-346, Lead Product Candidate for Hyperuricemia in the Setting of Advanced Chronic Kidney Disease
Jun 08, 2018: Selecta Biosciences to Present Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018
Nov 29, 2017: Nippon Chemiphar Announces Progress on Its Hyperuricemia/Gout Projects; NC-2500 Shows Favorable Profile to Lower Serum Uric Acid in Phase-1 Study
Apr 21, 2017: Mylan Receives CHMP Positive Opinion For Febuxostat
Dec 07, 2016: Selecta Presents Phase 1 Clinical Data for Lead Product Candidate, SEL-212, in Patients with Hyperuricemia at 11th Annual IMVAC Summit
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Hyperuricemia - Overview
Hyperuricemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hyperuricemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hyperuricemia - Companies Involved in Therapeutics Development
Allena Pharmaceuticals Inc
Arthrosi Therapeutics Inc
AstraZeneca Plc
FortuneRock (China) Ltd
Hinova Pharmaceuticals Inc
J-Pharma Co Ltd
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Nippon Chemiphar Co Ltd
NuBioPharma LLC
PegBio Co Ltd
Polaris Pharmaceuticals Inc
Shanghai Yingli Pharmaceutical Co Ltd
Suzhou Sinovent Pharmaceuticals Co Ltd
Teijin Pharma Ltd
Xiuzheng Pharmaceutical Group Co Ltd
Hyperuricemia - Drug Profiles
(allopurinol +verinurad) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABP-671 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALLN-346 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
allopurinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AR-882 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
febuxostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HP-501 SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JPH-367 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NC-2500 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NC-2700 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PB-348 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegadricase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Urate Oxidase Replacement for Acute Hyperuricemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SFR-9350 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-4640 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
taininade - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TEI-A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TMX-049 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
verinurad - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XNW-3009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YL-90148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hyperuricemia - Dormant Projects
Hyperuricemia - Discontinued Products
Hyperuricemia - Product Development Milestones
Featured News & Press Releases
Sep 08, 2020: Allena Pharmaceuticals doses first subject in phase 1 clinical trial of ALLN-346, in development for the treatment of d advanced chronic kidney disease
Oct 30, 2019: AstraZeneca to present pivotal roxadustat phase II data at the American Society of Nephrology Kidney Week 2019
Oct 17, 2019: Allena Pharmaceuticals to present new data on ALLN-346 at upcoming ACR/ARP Annual Meeting
Jul 17, 2019: Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease
Jun 21, 2019: FDA Joint Committee recommends approval of Uloric (Febuxostat)
Jun 13, 2019: Verinurad with febuxostat significantly reduces albuminuria and hyperuricaemia in patients with type ii diabetes in phase iia trial
Jan 11, 2019: Takeda Announces Outcome of FDA Advisory Committee Meeting to Review Uloric (febuxostat) Cardiovascular Outcomes Trial Results
Nov 01, 2018: Selecta Biosciences to provide update on SEL-212 development strategy, including planned head-to-head study versus Krystexxa
Oct 22, 2018: Allena Pharmaceuticals presents preclinical data demonstrating normalized urine uric acid excretion and plasma urate reduction following treatment with ALLN-346
Oct 18, 2018: Allena Pharmaceuticals to present data on Kidney Disease drug candidate ALLN-346 at ACR/ARHP 2018 Annual Meeting
Jun 19, 2018: Allena Pharmaceuticals Completes Animal Proof-of-Concept Study for ALLN-346, Lead Product Candidate for Hyperuricemia in the Setting of Advanced Chronic Kidney Disease
Jun 08, 2018: Selecta Biosciences to Present Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018
Nov 29, 2017: Nippon Chemiphar Announces Progress on Its Hyperuricemia/Gout Projects; NC-2500 Shows Favorable Profile to Lower Serum Uric Acid in Phase-1 Study
Apr 21, 2017: Mylan Receives CHMP Positive Opinion For Febuxostat
Dec 07, 2016: Selecta Presents Phase 1 Clinical Data for Lead Product Candidate, SEL-212, in Patients with Hyperuricemia at 11th Annual IMVAC Summit
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Hyperuricemia, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Hyperuricemia - Pipeline by Allena Pharmaceuticals Inc, H2 2020
Hyperuricemia - Pipeline by Arthrosi Therapeutics Inc, H2 2020
Hyperuricemia - Pipeline by AstraZeneca Plc, H2 2020
Hyperuricemia - Pipeline by FortuneRock (China) Ltd, H2 2020
Hyperuricemia - Pipeline by Hinova Pharmaceuticals Inc, H2 2020
Hyperuricemia - Pipeline by J-Pharma Co Ltd, H2 2020
Hyperuricemia - Pipeline by Jiangsu Atom Bioscience and Pharmaceutical Co Ltd, H2 2020
Hyperuricemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2020
Hyperuricemia - Pipeline by Nippon Chemiphar Co Ltd, H2 2020
Hyperuricemia - Pipeline by NuBioPharma LLC, H2 2020
Hyperuricemia - Pipeline by PegBio Co Ltd, H2 2020
Hyperuricemia - Pipeline by Polaris Pharmaceuticals Inc, H2 2020
Hyperuricemia - Pipeline by Shanghai Yingli Pharmaceutical Co Ltd, H2 2020
Hyperuricemia - Pipeline by Suzhou Sinovent Pharmaceuticals Co Ltd, H2 2020
Hyperuricemia - Pipeline by Teijin Pharma Ltd, H2 2020
Hyperuricemia - Pipeline by Xiuzheng Pharmaceutical Group Co Ltd, H2 2020
Hyperuricemia - Dormant Projects, H2 2020
Hyperuricemia - Discontinued Products, H2 2020
Number of Products under Development for Hyperuricemia, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Hyperuricemia - Pipeline by Allena Pharmaceuticals Inc, H2 2020
Hyperuricemia - Pipeline by Arthrosi Therapeutics Inc, H2 2020
Hyperuricemia - Pipeline by AstraZeneca Plc, H2 2020
Hyperuricemia - Pipeline by FortuneRock (China) Ltd, H2 2020
Hyperuricemia - Pipeline by Hinova Pharmaceuticals Inc, H2 2020
Hyperuricemia - Pipeline by J-Pharma Co Ltd, H2 2020
Hyperuricemia - Pipeline by Jiangsu Atom Bioscience and Pharmaceutical Co Ltd, H2 2020
Hyperuricemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2020
Hyperuricemia - Pipeline by Nippon Chemiphar Co Ltd, H2 2020
Hyperuricemia - Pipeline by NuBioPharma LLC, H2 2020
Hyperuricemia - Pipeline by PegBio Co Ltd, H2 2020
Hyperuricemia - Pipeline by Polaris Pharmaceuticals Inc, H2 2020
Hyperuricemia - Pipeline by Shanghai Yingli Pharmaceutical Co Ltd, H2 2020
Hyperuricemia - Pipeline by Suzhou Sinovent Pharmaceuticals Co Ltd, H2 2020
Hyperuricemia - Pipeline by Teijin Pharma Ltd, H2 2020
Hyperuricemia - Pipeline by Xiuzheng Pharmaceutical Group Co Ltd, H2 2020
Hyperuricemia - Dormant Projects, H2 2020
Hyperuricemia - Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development for Hyperuricemia, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
COMPANIES MENTIONED
Allena Pharmaceuticals Inc
Arthrosi Therapeutics Inc
AstraZeneca Plc
FortuneRock (China) Ltd
Hinova Pharmaceuticals Inc
J-Pharma Co Ltd
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Nippon Chemiphar Co Ltd
NuBioPharma LLC
PegBio Co Ltd
Polaris Pharmaceuticals Inc
Shanghai Yingli Pharmaceutical Co Ltd
Suzhou Sinovent Pharmaceuticals Co Ltd
Teijin Pharma Ltd
Xiuzheng Pharmaceutical Group Co Ltd
Number of Products under Development for Hyperuricemia, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
COMPANIES MENTIONED
Allena Pharmaceuticals Inc
Arthrosi Therapeutics Inc
AstraZeneca Plc
FortuneRock (China) Ltd
Hinova Pharmaceuticals Inc
J-Pharma Co Ltd
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Nippon Chemiphar Co Ltd
NuBioPharma LLC
PegBio Co Ltd
Polaris Pharmaceuticals Inc
Shanghai Yingli Pharmaceutical Co Ltd
Suzhou Sinovent Pharmaceuticals Co Ltd
Teijin Pharma Ltd
Xiuzheng Pharmaceutical Group Co Ltd
